Glucocorticoid efficacy in asthma: is improved tissue remodeling upstream of anti-inflammation.
Synthetic glucocorticoids (GCs), such as prednisone, are among the most widely prescribed drugs worldwide and are used to treat many acute and chronic inflammatory conditions. The current paradigm of GC efficacy is that they are potent anti-inflammatory agents. Decreased inflammation in many disorders is thought to lead to decreased pathological tissue remodeling. However, this model has never been validated. In particular, improvements in inflammation have not been shown to improve the rate of lung function decline in asthma. Herein, we present an alternative paradigm, where GC efficacy is mediated through more successful tissue remodeling, with reduction in inflammation secondary to successful regeneration.
Freishtat
Robert J
RJ
Children's National Medical Center, Washington, DC 20010, USA. rfreishtat@cnmcresearch.org
Nagaraju
Kanneboyina
K
Jusko
William
W
Hoffman
Eric P
EP
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D002453:Cell Cycle / Q000187:drug effects; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids